| Bioactivity | Pegcetacoplan acetate is a pegylated complement C3 inhibitor peptide. Pegcetacoplan acetate acts by binding with complement component 3 (C3) and its activation fragment C3b. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including age-related macular degeneration, C3 glomerulopathy, Geographic atrophy (GA) and autoimmune haemolytic anaemia[1][2]. |
| Formula | (C2H4O)nC170H248N50O47S4.xC2H4O2 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. David S Liao, et al. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020 Feb;127(2):186-195. [2]. Sheridan M Hoy, et al. Pegcetacoplan: First Approval. Drugs. 2021 Aug;81(12):1423-1430. [3]. https://pubmed.ncbi.nlm.nih.gov/34342834/ |
Pegcetacoplan acetate
CAS: F: (C2H4O)nC170H248N50O47S4.xC2H4O2 W:
Pegcetacoplan acetate is a pegylated complement C3 inhibitor peptide. Pegcetacoplan acetate acts by binding with complem
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.